熱門資訊> 正文
MoonLake Immunotherapeutics每股收益为-0.22美元,损失0.01美元
2024-05-08 00:15
- MoonLake Immunotherapeutics press release (NASDAQ:MLTX): Q1 EPS of -$0.22 misses by $0.01.
- The company ended the quarter with $547.1M in cash
More on MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
- Goldman starts MoonLake at neutral, cites lead drug potential
- MoonLake gets FDA, EMA feedback on Phase 3 study
- Seeking Alpha’s Quant Rating on MoonLake Immunotherapeutics
- Historical earnings data for MoonLake Immunotherapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。